![]() | Only 14 pages are availabe for public view |
Abstract SUMMARY AND CONCLUSION Non-alcoholic fatty liver disease (NAFLD) is a condition of chronic hepatic fat accumulation ranging from indolent fat deposition to severe lipotoxicity-induced steatohepatitis with necroinflammation. It represents a>major health problem associated with an increased risk of liver cirrhosis, HCC, and metabolic problems with a significantly rising prevalence probably related to the increasing incidence of obesity and type 2 DM. Over the last decades, DM represents one of the major health problems worldwide and a socio-economic burden for developing countries with a significantly rising global prevalence. The increased morbidity and mortality in type 2 DM are related not only to the associated atherosclerosis, CVD, CeVD, and CKD but also to a wide range of chronic liver diseases. Recently, it has been recognized that NAFLD represents an important burden of disease for patients with type 2 DM. Individuals with type 2 DM not only have a high prevalence of NAFLD, up to 70% but also seem to have increased severity of the disease. Therefore, it is very important to diagnose NAFLD early and manage it properly in a primary stage which will enhance prognosis and prevent secondary complications. Liver biopsy is invasive so cannot be used widely in the general population. Blood serum transaminase has a very low sensitivity and is normal in most cases. Although radiologic investigations, such as US and MRI, have high sensitivity, they are not cost-effective. On the other hand, anthropometric indices have been widely used as simple and feasible tools for screening metabolic disorders |